Blue-Chip Drug Stock Could Keep Lapping Broader Market

This post was originally published on this site

Schaeffer’s Investment Research was built from scratch on Bernie Schaeffer’s vision of providing accessible professional-grade trading information to retail traders. This remains our mission today, 41 years later. To access the entirety of the Schaeffer’s 41st Anniversary Stock Picks report, click here.

Blue-chip pharma stock Merck & Co., Inc. (NYSE:MRK) has strongly outperformed the broader market, to the tune of a nearly 22% year-to-date gain. The shares broke out in 2022 from a three-year major consolidation area, which was capped by the round-number $200 billion market cap level. With this level now cleared, there’s enough pessimism around Merck stock that could unwind and fuel a sustained push higher.

MRK stock, Merck stock, stock picks

For starters, half of the 16 covering analysts sport tepid “hold” ratings, indicating a round of overdue upgrades could boost MRK.

Plus, the Merck stock options pits are swarming with put traders. At the ISE/CBOE/PHLX, MRK sports a 10-day put/call volume ratio of 1.06 that stands in the 97th annual percentile. Echoing this, MRK’s Schaeffer’s put/call volume ratio (SOIR) of 0.95 also ranks in the highest percentile of the past 12 months. In other words, short-term options traders are much more put-biased toward Merck stock than usual at the moment.

Tony Venosa, CMT, is a Senior Options Strategist at Schaeffer’s Investment Research. He’s has over 20 years of trading experience under his belt — including a stint in the mid-’90s clerking in the S&P 500 trading pits in Chicago, plus time spent as a commodity broker and proprietary day trader. A graduate of Miami University with a B.S. in finance and decision sciences, Venosa earned his Chartered Market Technician designation in 2008, and has been part of Schaeffer’s in-house research team since 2010.